Literature DB >> 26199394

Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: a coming of age for AR splice variants?

C Sprenger1, T Uo1, S Plymate2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26199394      PMCID： PMC4551163          DOI： 10.1093/annonc/mdv311

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  12 in total

1.  EFFECT OF ORCHIECTOMY AND IRRADIATION ON CANCER OF THE PROSTATE.

Authors:  C Huggins
Journal:  Ann Surg       Date:  1942-06       Impact factor: 12.969

2.  Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.

Authors:  Michael T Schweizer; Emmanuel S Antonarakis; Hao Wang; A Seun Ajiboye; Avery Spitz; Haiyi Cao; Jun Luo; Michael C Haffner; Srinivasan Yegnasubramanian; Michael A Carducci; Mario A Eisenberger; John T Isaacs; Samuel R Denmeade
Journal:  Sci Transl Med       Date:  2015-01-07       Impact factor: 17.956

3.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  N Engl J Med       Date:  2014-09-03       Impact factor: 91.245

4.  Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer.

Authors:  Matthew R Cooperberg; Shiro Hinotsu; Mikio Namiki; Peter R Carroll; Hideyuki Akaza
Journal:  BJU Int       Date:  2015-05-14       Impact factor: 5.588

Review 5.  The link between androgen receptor splice variants and castration-resistant prostate cancer.

Authors:  Cynthia C T Sprenger; Stephen R Plymate
Journal:  Horm Cancer       Date:  2014-05-06       Impact factor: 3.869

6.  Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.

Authors:  M Nakazawa; C Lu; Y Chen; C J Paller; M A Carducci; M A Eisenberger; J Luo; E S Antonarakis
Journal:  Ann Oncol       Date:  2015-06-27       Impact factor: 32.976

7.  Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.

Authors:  Alison H M Reid; Gerhardt Attard; Daniel C Danila; Nikhil Babu Oommen; David Olmos; Peter C Fong; L Rhoda Molife; Joanne Hunt; Christina Messiou; Christopher Parker; David Dearnaley; Joost F Swennenhuis; Leon W M M Terstappen; Gloria Lee; Thian Kheoh; Arturo Molina; Charles J Ryan; Eric Small; Howard I Scher; Johann S de Bono
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

8.  Androgen receptor splice variants determine taxane sensitivity in prostate cancer.

Authors:  Maria Thadani-Mulero; Luigi Portella; Shihua Sun; Matthew Sung; Alexandre Matov; Robert L Vessella; Eva Corey; David M Nanus; Stephen R Plymate; Paraskevi Giannakakou
Journal:  Cancer Res       Date:  2014-02-20       Impact factor: 12.701

9.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

10.  Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

Authors:  Nicholas David James; Melissa R Spears; Noel W Clarke; David P Dearnaley; Johann S De Bono; Joanna Gale; John Hetherington; Peter J Hoskin; Robert J Jones; Robert Laing; Jason F Lester; Duncan McLaren; Christopher C Parker; Mahesh K B Parmar; Alastair W S Ritchie; J Martin Russell; Räto T Strebel; George N Thalmann; Malcolm D Mason; Matthew R Sydes
Journal:  Eur Urol       Date:  2014-10-06       Impact factor: 20.096
View more
  6 in total

1.  PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.

Authors:  Kanak Raina; Jing Lu; Yimin Qian; Martha Altieri; Deborah Gordon; Ann Marie K Rossi; Jing Wang; Xin Chen; Hanqing Dong; Kam Siu; James D Winkler; Andrew P Crew; Craig M Crews; Kevin G Coleman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-06       Impact factor: 11.205

Review 2.  Paxillin actions in the nucleus.

Authors:  Xiaoting Ma; Stephen R Hammes
Journal:  Steroids       Date:  2017-10-31       Impact factor: 2.668

3.  The Y-located proto-oncogene TSPY exacerbates and its X-homologue TSPX inhibits transactivation functions of androgen receptor and its constitutively active variants.

Authors:  Yunmin Li; Dong Ji Zhang; Yun Qiu; Tatsuo Kido; Yun-Fai Chris Lau
Journal:  Hum Mol Genet       Date:  2017-03-01       Impact factor: 6.150

4.  Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer.

Authors:  Markéta Škereňová; Veronika Mikulová; Otakar Čapoun; David Švec; Katarína Kološtová; Viktor Soukup; Hana Honová; Tomáš Hanuš; Tomáš Zima
Journal:  Mol Diagn Ther       Date:  2018-06       Impact factor: 4.074

5.  Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer.

Authors:  Mark C Markowski; John L Silberstein; James R Eshleman; Mario A Eisenberger; Jun Luo; Emmanuel S Antonarakis
Journal:  JCO Precis Oncol       Date:  2017-10-30

Review 6.  Galeterone for the treatment of advanced prostate cancer: the evidence to date.

Authors:  Diogo A Bastos; Emmanuel S Antonarakis
Journal:  Drug Des Devel Ther       Date:  2016-07-15       Impact factor: 4.162
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.